公开(公告)号：US20240109972A1

公开(公告)日：2024-04-04

申请号：US18038818

申请日：2021-12-07

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria JURE-KUNKEL ,  Manish GUPTA ,  Tahamtan AHMADI ,  Kathy AMIRI ,  Gaurav BAJAJ

IPC: C07K16/28 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505

Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.

公开(公告)号：US20190233522A1

公开(公告)日：2019-08-01

申请号：US16316000

申请日：2017-07-07

Applicant: GENMAB A/S

Inventor： Ulf FORSSMANN ,  Steen LISBY ,  Nedjad LOSIC

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: An antibody-drug conjugate (ADC) based on an antibody binding to human AXL and pharmaceutical compositions comprising the ADC for use in the treatment of a cancer comprising administering to a subject a weekly dose of from about 0.45 mg/kg to about 2.0 mg/kg of the ADC once a week for three consecutive weeks followed by a one week resting period without any administration of the ADC so that each cycle time is 28 days including the resting period.

公开(公告)号：US20230087164A1

公开(公告)日：2023-03-23

申请号：US17795318

申请日：2021-02-04

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Isil ALTINTAS ,  Ulf FORSSMANN ,  Kate SASSER ,  Maria JURE-KUNKEL ,  Manish GUPTA

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.

公开(公告)号：US20220273809A1

公开(公告)日：2022-09-01

申请号：US17628382

申请日：2020-07-17

Applicant: GENMAB A/S

Inventor： Maarten JANMAAT ,  Nora PENCHEVA ,  Esther Cornelia Wilhelmina BREIJ ,  Julia BOSHUIZEN ,  Daniel Simon PEEPER ,  Ulf FORSSMANN ,  Tahamtan AHMADI ,  Patricia Garrido CASTRO

IPC: A61K47/68 ,  A61P35/00 ,  A61K47/02

Abstract: The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl.

公开(公告)号：US20240262924A1

公开(公告)日：2024-08-08

申请号：US18570257

申请日：2022-06-20

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria N. JURE-KUNKEL ,  Gaurav BAJAJ ,  Craig THALHAUSER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.

公开(公告)号：US20210393793A1

公开(公告)日：2021-12-23

申请号：US17279359

申请日：2019-09-26

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  Ulf FORSSMANN ,  Tahamtan AHMADI

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K9/00

Abstract: The present invention relates to immunoconjugates anti-AXL antibodies and compositions for treatment of non-small cell lung cancer.

公开(公告)号：US20210070869A1

公开(公告)日：2021-03-11

申请号：US17046199

申请日：2019-04-10

Applicant: GENMAB A/S

Inventor： Maarten JANMAAT ,  Esther BREIJ ,  Ulf FORSSMANN ,  Tahamtan AHMADI ,  Julia BOSHUIZEN ,  Daniel PEEPER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.